3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Disease Progression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma in Situ
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
3
Trastuzumab
2
Nivolumab
2
tucatinib
1
regorafenib
1
pertuzumab
1
niraparib
1
milademetan
1
dostarlimab
1
cobimetinib
1
brigimadlin
1
atezolizumab
1
alectinib
1
Vemurafenib
1
Tomography, X-Ray Computed
1
Ramucirumab
1
Radiation
1
Positron-Emission Tomography
1
Paclitaxel
1
Magnetic Resonance Imaging
1
HhAntag691
1
Fulvestrant
1
Erlotinib Hydrochloride
1
Clinical Trials, Phase II as Topic
1
Carboplatin
1
Brachytherapy
1
Antibodies
1
AZD9833
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Clinical Trials, Phase II as Topic
×
Genitourinary
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled